Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-based Protein Subunit Vaccine (ZF2001) Against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials.